Product Information

COVISHIELD - product monograph

Health Canada has reviewed the manufacturing information for these vaccines and found them to be comparable.


  • Individuals 18 years and older


  • 2x 0.5 ml doses given IM (preferably deltoid)
  • The 2nd dose should be given between 4 and 12 weeks after the 1st
    • NOTE: As of March 3, 2021, NACI recommends that in the context of limited COVID-19 vaccine supply, jurisdictions should maximize the number of individuals benefiting from the first dose of vaccine by extending the interval for the second dose of vaccine to 4 months. This recommendation is subject to revision as evidence evolves.

Adverse Effects

Only short to medium term data are available at this time. Surveillance will continue for long-term adverse effects.

The most commonly reported adverse effects included:  

  • injection site tenderness
  • injection site pain
  • fatigue
  • headache
  • myalgia
  • malaise
  • pyrexia
  • chills
  • arthralgia
  • nausea

Drug Interactions

  • There are no known drug interactions. 


  • Under 18 years of age
    • The COVISHIELD vaccine is approved for use in persons 18 years of age and older.
  • History of anaphylaxis following previous dose of the vaccine.
  • Reported hypersensitivity to one of the ingredients. See product monograph for ingredients. 
  • Other information will be added as it becomes available from NACI.
  • Currently feeling unwell with symptoms that could be COVID-19.
    • to avoid confusion if symptoms arise/worsen as they could be adverse effects of the vaccine or because of the underlying infection
    • to prevent potential transmission to others who are at the vaccine clinic/site (clients should be following public health quarantine recommendations)
  • Serious adverse or allergic reaction to previous dose of COVID-19 vaccine unless determined safe by an allergist or other healthcare provider.

Other information will be added as it becomes available from NACI.

Current Infection

  • Clients with current infection should not present for vaccination to prevent transmission to others at the vaccination clinic/site and should follow public health quarantine recommendations.

Past Infection

  • If acute symptoms have resolved and all quarantine orders have been followed, the client can be vaccinated.
    • However, the recommendation is for clients to wait 3 months to take advantage of the client's natural immunity and to leave the current supply of vaccine for others without immunity.
    • Trial included <10% participants with COVID-19 infection proven by serology.
At this time, NACI is recommending: 
  • The COVID-19 vaccines should be administered at least 14 days AFTER any other vaccines (live or inactivated).
  • Other vaccines should be avoided for 28 days AFTER receiving the last COVID-19 vaccine dose.
  • Exception: If a patient requires a vaccination as part of a post-exposure prophylaxis protocol, it should be administered. 
At this time, individuals should complete the vaccination course with COVISHIELD. There are no data available on the interchangeability of COVISHIELD with other non ChAdOx1-S (recombinant) COVID-19 vaccines.